Editorial

Your role in establishing the real bioceconomy

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the European Commission on 13 February 2012, offers a unique approach to addressing these challenges in a comprehensive way.
In order to reduce heavy economic dependency on fossil resources and focus on mitigating climate change, Europe needs to move towards a post-petroleum society. The Bio­economy Strategy will contribute to this transition by promoting research and innovation into sustainable production and exploitation of renewable raw materials, along with alternative energy and carbon sources. It will pave the way to a more innovative and low-carbon society that reconciles food security with the sustainable use of renewable biological resources for industrial purposes, while simultaneously creating new job opportunities. Biotechnology as an enabling technology will play a crucial role in enhancing sustain­ability and competitiveness in the EU’s primary production and processing industries. It will also significantly contribute to reducing EU industry dependence on fossil resources, and improve the resource efficiency of production processes through the use of renewable raw materials (including wastes) and more environmentally-friendly bio-based processes.
The Bioeconomy Strategy is based on three complementary pillars. The first is aimed at increasing investment in research, innovation and skills. Under the European Framework “Horizon 2020” (2014-2020) Programme for Research and Innovation, €4.7bn of funding has been earmarked for bioeconomy research and innovation under the societal challenge “Food security, sustainable agriculture, marine and maritime research, and the bioeconomy” and for bio­technology as an enabling technology. It is estimated that this funding could generate about 130,000 new jobs and €45bn in value added in bioeconomy sectors by 2025, not taking into account other direct and indirect public and private investments into bioeconomy sectors. A Public Private Partnership for bio-based industries is under consideration.
The second pillar aims to improve synergies and coherence between priorities of European research and innovation policy and other policies relevant to the bioeconomy. It will provide different platforms to enhance interactions between researchers, policymakers, industries and society, as well as supporting similar initiatives in the EU Member States and Regions. The Strategy will also further develop international cooperation in the area of the bioeconomy.
In its third pillar, the Strategy provides support to new markets and the expansion of existing ones; for example, by promoting the develop­ment of standards, sustainability assessments and labels for bio-based products that will help facilitate their uptake in consumer markets and by green procurement. This promotes both the establishment of networks of integrated and diversified biorefineries, and demonstration and pilot plants across Europe. Finally, the Stra­tegy promotes the development of science-based approaches that can better inform consumers about product properties (like environmental sustainability) and aid in the promotion of a healthy and sustainable lifestyle.
Five Commissioners have demonstrated their strong commitment to the bioeconomy by co-signing the Bioeconomy Strategy. However, its success will very much depend on the commitment of member states, regions, stakeholders in the research and innovation community and citizens – like you.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/article/your-role-in-establishing-the-real-bioceconomy.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper